| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JAK3 |
| Uniprot No | P52333 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 811-1124aa |
| 氨基酸序列 | CQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JAK3重组蛋白的3篇代表性文献，包含文献名称、作者及摘要内容的简要概括：
---
1. **文献名称**：*Structural and functional characterization of the JH2 domain of JAK3 recombinant protein*
**作者**：Smith A, et al.
**摘要**：本研究通过X射线晶体学解析了JAK3重组蛋白JH2结构域的3D结构，揭示了其自抑制机制，并证明JH2结构域通过调控激酶活性参与JAK-STAT信号通路的负向调节。
2. **文献名称**：*Expression and purification of active recombinant JAK3 kinase for drug screening*
**作者**：Chen L, et al.
**摘要**：开发了一种高效的大肠杆菌表达系统，成功获得具有催化活性的重组JAK3激酶蛋白，验证其在体外药物筛选中的应用潜力，为JAK3抑制剂开发提供实验工具。
3. **文献名称**：*JAK3 mutations and recombinant protein analysis in severe combined immunodeficiency (SCID)*
**作者**：Wang Y, et al.
**摘要**：通过构建携带SCID相关JAK3突变的重组蛋白，发现特定突变(如L857P)导致激酶活性丧失和STAT5磷酸化能力受损，为遗传性免疫缺陷的分子机制提供了新见解。
---
**注**：以上文献为示例性质，实际引用需根据具体研究需求检索最新权威论文(如PubMed/Web of Science数据库中的文章)。
Janus kinase 3 (JAK3) is a non-receptor tyrosine kinase belonging to the Janus kinase family, which plays a critical role in cytokine receptor signaling. Unlike other JAK members (JAK1. JAK2. TYK2), JAK3 is predominantly expressed in hematopoietic cells and associates with the common gamma chain (γc) subunit of receptors for interleukins such as IL-2. IL-4. IL-7. IL-9. IL-15. and IL-21. This restricted expression pattern links JAK3 to immune system regulation, particularly in lymphocyte development, activation, and homeostasis.
Structurally, JAK3 contains seven JAK homology (JH) domains. The JH1 domain is the catalytic kinase region, while JH2 acts as a regulatory pseudokinase domain. Mutations in JAK3. especially in JH2. can lead to constitutive activation or loss of function, contributing to immune disorders. For instance, inactivating mutations cause severe combined immunodeficiency (SCID), while hyperactivation is implicated in autoimmune diseases and hematologic malignancies.
Recombinant JAK3 protein is engineered for research and therapeutic applications. Produced in systems like *E. coli* or mammalian cells, it retains enzymatic activity and is used to study JAK3-STAT signaling mechanisms, screen inhibitors, or model disease pathways. Its purification often involves affinity tags (e.g., His-tag) for high yield and specificity.
Pharmacologically, JAK3 is a target for immunosuppressive therapies. Selective JAK3 inhibitors (e.g., tofacitinib, ritlecitinib) aim to block aberrant signaling in autoimmune conditions like rheumatoid arthritis and alopecia areata, minimizing off-target effects seen with broader JAK inhibitors. Recombinant JAK3 also aids in structural studies to design isoform-specific drugs, addressing challenges in kinase selectivity.
Overall, JAK3 recombinant protein serves as a vital tool for dissecting immune signaling and advancing targeted therapies, bridging molecular insights with clinical innovation.
×
